The recent success of inebilizumab, a recently FDA‐approved anti‐CD19 monoclonal with an 87% disease flare reduction in a Phase III trial [18], marks a significant advancement in managing IgG4‐RD, offering effective alternatives to corticosteroids and hope for reduced side effects and improved disease control. This evidence concerns the gene CD19 and immunoglobulin G4-related sclerosing disease.